Zynerba Pharmaceuticals

Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

– European Commission granted orphan drug designation for Zygel™ in Fragile X syndrome (FXS) –

Zynerba Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

Provides 10-year market exclusivity in EU upon regulatory approval Provides 10-year market exclusivity in EU upon regulatory approval

Zynerba Pharmaceuticals Announces European Commission Has Granted Orphan Drug Designation for Zygel™ in Fragile X Syndrome

Topline data from Phase 2 INSPIRE trial expected mid-year 2022 Topline data from Phase 2 INSPIRE trial expected mid-year 2022

Zynerba Pharmaceuticals Announces Completion of Enrollment in Phase 2 Trial of Zygel™ in 22q11.2 Deletion Syndrome

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc has announced the appointment of Albert P Parker as the company's new chief legal officer and corporate secretary.  Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, will assume the duties of Suzanne Hanlon, who will retire from her position at the end of February 2022, the company said.

Zynerba Pharmaceuticals appoints Albert Parker as its new chief legal officer upon retirement of Suzanne Hanlon at end-February

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) has appointed Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as chief legal officer and corporate secretary.

Zynerba Pharmaceuticals Names New CLO & Corporate Secretary

DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire from her position at the end of February 2022.

Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) has decided not to advance Zygel against developmental and epileptic encephalopathies (DEE). The decision was in line with the feedback from the FDA, which indicated that the selection of a specific DEE syndrome would be required to support its clinical trials for a pediatric indication, the company said.

Zynerba Discontinues Development Of Cannabidiol Gel In Epileptic Disorders

Zynerba Pharmaceuticals Inc has provided program updates for Fragile X syndrome (FXS), autism spectrum disorder (ASD), 22q11.2 deletion syndrome (22q), and developmental and epileptic encephalopathies (DEE).  In addition to the continued clinical development of its Zygel CBD gel in FXS, the company said it plans to focus on the development of Zygel in ASD and 22q.

Zynerba announces clinical updates for Fragile X and 22q11.2 deletion syndromes, autism spectrum disorder, and developmental and epileptic encephalopathies

– Company plans to focus development of Zygel™ in FXS, ASD and 22q –

Zynerba Pharmaceuticals Announces Clinical Development Updates for FXS, ASD, 22q and DEE

DEVON, Pa., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced presentation details for The BRAIN Foundation Synchrony 2021 Symposium, being held virtually December 11-12, 2021. The presentation can be accessed by registering for free at https://synchronysymposium.com/. A copy of the presentation slides will be made available on the Zynerba corporate website following the presentation at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Announces Presentation at The BRAIN Foundation Synchrony 2021 Symposium

Focused on treating rare epilepsies and neuropsychiatric disorders Lead candidate Zygel targeted at multiple conditions RECONNECT trial with Zygel for Fragile X syndrome in 3Q 2021 What Zynerba does: Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is doing trailblazing work pushing clinical trials for cannabis-derived treatments. The specialty pharma company is developing novel transdermal CBD treatments for patients suffering rare epilepsies and neurological disorders.

Zynerba's CBD skin gel Zygel offers a potential goldmine of therapies for Fragile X syndrome and other conditions

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) Inc reported it has further expanded its intellectual property (IP) portfolio covering its Zygel CBD skin gel, with the award of an EU patent.  The European patent office has now issued a patent entitled: "Treatment of Fragile X Syndrome and Autism with Cannabidiol," the pharma group said in a brief statement.

Zynerba Pharmaceuticals further boosts patent portfolio for its Zygel CBD gel

DEVON, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that the European Patent Office has issued Patent No. 3687513, titled “Treatment of Fragile X Syndrome and Autism with Cannabidiol,” which includes claims directed to methods of treating one or more behavioral symptoms of Fragile X syndrome and methods of treating one or more behavioral symptoms of autism spectrum disorder by transdermally administering a therapeutically effective amount of cannabidiol (CBD).

Zynerba Pharmaceuticals Announces Issuance of New Patent in EU for Zygel™

Zynerba Pharmaceuticals (NASDAQ:ZYNE) Inc reported its 3Q financial results showing a strong cash position of $75.6 million in the bank. The figure was well up from the $59.2 million it reported as of December 31, 2020.

Zynerba Pharmaceuticals ends 3Q with $75.6 million in the bank

– Initiated RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X Syndrome (FXS); topline results expected second-half 2023 –

Zynerba Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights

DEVON, Pa., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced oral and poster presentations at the Society for Developmental & Behavioral Pediatrics Annual Meeting, being held virtually October 21-25, 2021, and the 68th American Academy of Child & Adolescent Psychiatry Annual Meeting, being held virtually October 18-30, 2021.

Zynerba Pharmaceuticals Announces Presentations at Two Upcoming Scientific Conferences in October

DEVON, Pa., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit being held virtually October 18-19, 2021.

Zynerba Pharmaceuticals Announces Presentation of Poster at the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit

DEVON, Pa., Oct. 08, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the presentation of a poster at the 2021 American Academy of Pediatrics (AAP) National Conference & Exhibition, which will be held virtually from October 8-11, 2021. A copy of the poster titled, “Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study (BRIGHT [ZYN2-CL-030]),” will be made available on the Zynerba corporate website starting today, October 8, 2021 at http://zynerba.com/publications/. Additional meeting information can be found on the AAP website at aapexperience.org.

Zynerba Pharmaceuticals Announces Presentation of Poster at the 2021 American Academy of Pediatrics National Conference & Exhibition

Dermata Therapeutics

9 Meters Biopharma

Verastem

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top Penny Stocks To Buy The Dip According To Analysts In September

DEVON, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will participate in a fireside chat during the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 11:20 a.m. ET.

Zynerba Pharmaceuticals to Present at the Cantor Virtual Global Healthcare Conference

Zynerba Pharmaceuticals Inc has announced the initiation of a pivotal, multinational randomized, double-blind, placebo-controlled, multiple-center (RECONNECT) Phase 3 trial to evaluate the efficacy and safety of Zygel (cannabidiol formulated in a transdermal gel) in children and adolescents with Fragile X syndrome (FXS).  The company said the trial is planned to confirm the positive results observed in a population of responders in its CONNECT-FX trial, a randomized, double-blind, placebo-controlled trial that assessed the efficacy and safety of Zygel as a treatment for the behavioral symptoms of FXS.

Zynerba initiates RECONNECT Phase 3 trial of Zygel for Fragile X syndrome

Trial will evaluate the efficacy and safety of Zygel in children and adolescents with  Fragile X Syndrome

Zynerba Pharmaceuticals Initiates RECONNECT, a Pivotal Phase 3 Trial of Zygel™ in Fragile X Syndrome

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment period. Zygel is cannabidiol formulated in a transdermal gel.

Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children

Zynerba Pharmaceuticals Inc. has presented data from the Phase 2 BRIGHT trial describing the tolerability and efficacy of its Zygel transdermal cannabinoid therapy in children and adolescents with autism spectrum disorder (ASD) over a longer-term, 38-week treatment period.

Zynerba presents longer-term tolerability and efficacy data of Zygel in children and adolescents with autism spectrum disorder

DEVON, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today presented data from the Phase 2 BRIGHT trial describing tolerability and efficacy of Zygel (cannabidiol formulated in a transdermal gel [ZYN002]) in children and adolescents with autism spectrum disorder (ASD) over a longer term, 38-week treatment period. These data were presented as an oral presentation at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021 being held virtually from September 9-10, 2021. A copy of the presentation is available on the Zynerba corporate website at http://zynerba.com/publications/.

Zynerba Pharmaceuticals Presents Longer Term Tolerability and Efficacy Data of Zygel™ in Children and Adolescents with Autism Spectrum Disorder (ASD) at The Society for the Study of Behavioural Phenotypes (SSBP) Conference 2021

News for Zynerba Pharmaceuticals Stock (ZYNE)